- You can view the full Momenta Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
President-elect Trump's vague healthcare policy has put the $3 trillion industry on edge.
Momenta Pharmaceuticals' (MNTA) stock rating was raised to 'overweight' at Barclays on Tuesday.
Momenta may be a good option for value-oriented investors, while Coherus may be better for those who prefer a company that is likely to gain momentum.
The market action is solid today as my hunt for individual stock picks continues.